Immunization
42
4
4
27
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 42 trials
100.0%
+13.5% vs benchmark
33%
14 trials in Phase 3/4
26%
7 of 27 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 27 completed trials
Clinical Trials (42)
GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose
Influenza Immunization in Adults Over Age 75
Safety and Efficacy of BK1310 Intramuscular Injection in Healthy Infants
Post-marketing Surveillance Study for the Safety of Efluelda Tetra Pre-filled Syringe.
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
The Dreamy Jet Study
Description of the Immune Response to Yellow Fever Vaccination
Pediatric Vaccinations
mHealth-Assisted Conditional Cash Transfers to Improve Timeliness of Vaccinations (D0271)
The STOP-HPV Trial 1: Communication Intervention
HPV Vaccination Study in Postpartum Women
Adjuvant Effect of Physical Exercise on Immune Response to COVID-19 Vaccination and Interactions With Stress
Comparing the Use of a Mobile App for Surveillance of Adverse Events Following Influenza Immunization to a Web-Based Platform
The STOP-HPV Trial 6: Single Arm Evaluation of the Maintenance of the STOP-HPV Bundle
The STOP-HPV Trial 5: Single Arm Evaluation of the Bundle
FluPRINT Study: Characterisation of the Immune and Transcriptional Response to LAIV
The STOP-HPV Trial 3: Prompts Intervention
The STOP-HPV Trial 4: Bundle Intervention
State Immunization Information Systems to Improve HPV Vaccination Rates
The STOP-HPV Trial 2: Performance Feedback Intervention